Upload
thess1121
View
312
Download
2
Embed Size (px)
DESCRIPTION
R&D Program Valuation and Prioritization - Keys to Being a Strategic Business Partner to the R&D Organization
Citation preview
Drug Development• This is not for the faint of heart or the
poor!• It always takes longer and costs more
than projected!• If they tell you they only need another
$X million throw them out!
Macro Issues
• Funding is difficult to come by• Investors expect results from R&D• Pipe lines have holes• Revenue cliff• Goal approved drug/marketable product
Lesson Learned
• Is the Finance role much different in a manufacturing environment than an R&D organization?
• Edgcomb metals Plant manager put his best people on Inventory Management
Recommendation #1
• In order to support the R&D project teams as a finance resource and business partner– Put your best finance people on the R&D area• External reporting• Internal reporting
– Increased emphasis– Assist R&D with putting together and accurate projection– Monitor monthly activity
» Actual $ spent plus ESTIMATE to complete = total spend
Recommendation #2• Engage with R&D leaders – Finance must attend the project meetings and
issue a report to controller/CFO• Finance understands the big picture as funds move
from R to D to CMC to Regulatory to Marketing• Changes in direction cause changes in spending• When to pull the plug!• Provide real feedback on $ spent
Recommendation #3• Finance Department’s role as an advisor to
R&D on business decisions– Cash is limited.– Every project cannot be funded.– Existing projects must be managed• Expectations must be set with respect to cost• “What if” scenarios need to be addressed.
– Additional trials, managing vendors
Recommendation #4Enhancing Financial Planning Systems
• Finance must drive the planning process.– Start with excel before moving to complicated
software.– Top down to kick off the process– Bottom up approach to provide a roadmap• Pre-fill the budget amounts to get the process started.
Example 1Top Down Approach
Assumption – 2 year’s of Cash on hand
Description $Anidulafungin 10,000,000Dalbavancin 5,000,000Marketing 5,000,000G&A 5,000,000Total 25,000,000
Example of bottom up(000’s)
Dalbavancin Q1 Q2 Q3 Q4 Total
Clinical Trial $ 700 $700 $700 $700 $2,800
Toxicology $200 $200 $200 $200 $800
CMC $250 $250 $250 $250 $1,000
Travel $100 $100 $100 $100 $400
$5,000
Recommendation #5• Finance must manage the Budget and Forecasting
process– Buckets, Ranges and Cushions – One cost center per project
• Gl accounts – not too many and not to few
– Provide hard copy summary to R & D combined with an end of month meeting to discuss results.
– Rolling forecasts • Monthly preferred • Quarterly at a minimum• Prior year carryovers.
Recommendation #6 Assessing the Economics of an R&D
• Engage ex FDA consultants to review:– Preclinical– Clinical– CMC– NDA
• Perform a robust marketing study for the target.– Start with the end in mind.
Recommendation #7 Cost Management and Bench Marking
• Cost per patient– How does it compare to other studies?– How does it compare to other companies?
• Bring major vendors into the office quarterly.• Prevent cost over runs before they occur.
Recommendation #8 Accounting for Clinical Grants & Internal
Development
• Assign a specific person to monitor– Excel templates.– Time sheets– External review by a third party.